{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"retatrutide-sciatica","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-sciatica/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/retatrutide-sciatica/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-sciatica/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-sciatica/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-sciatica/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-sciatica/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-sciatica/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"retatrutide-sciatica","title":"Retatrutide for Sciatica: Weight-Loss Load Reduction and Layered Repair Evidence","register":"source_ledger","tags":["peptide","matrix"],"updated_at":"2026-07-17T02:41:20.716Z","body_excerpt":"## What's breaking down if you have Sciatica\n\nSciatica involves pain along the sciatic nerve path, often triggered by disc herniation, spinal stenosis, or other compression at a nerve root. The nerve signals ongoing damage or irritation from mechanical pressure. Suppressing that signal alone leaves the compression in place, so the underlying breakdown continues.\n\nExcess body weight increases compressive forces through the lumbar spine, hips, and kinetic chain. Each extra pound multiplies load on discs and facets. When breakdown exceeds repair capacity at the tissue, vascular, cellular, or neural level, symptoms persist or recur.\n\n## Why Retatrutide might help you\n\n1. You have Sciatica — breakdown is outpacing repair.\n2. What keeps failing: Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\n3. What Retatrutide is studied to do: Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\n4. Therefore for you: If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n5. This article centers Retatrutide; see other sections for BPC-157, TB-500, ARA-290 — different layers, same condition.\n6. Mechanical load: Rough rule used in spine biomechanics — each 1 lb of body weight lost can mean on the order of ~4 lb less compressive load through the lumbar spine (leverage through the kinetic chain).\n7. Retatrutide is studied for meaningful weight loss (GLP-1 / incretin pathways).\n8. Chain for you: more weight → more disc and facet load → faster degeneration and nerve irritation; Retatrutide → weight loss → less load → less ongoing breakdown. That is load reduction, not disc regeneration — it gives repair peptides less damage to fight.\n\n## Why BPC-157 might help you\n\n1. You have Sciatica — breakdown is outpacing repair.\n2. What keeps failing: Poor blood supply at injury, weak collagen organization, slow tissue turnover.\n3. What BPC-157 is studied to do: Studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue.\n4. Therefore for you: If that layer is part of your problem, BPC-157 is discussed because it targets repair (structure / tissue) — not because it masks pain.\n\n## Why TB-500 might help you\n\n1. You have Sciatica — breakdown is outpacing repair.\n2. What keeps failing: Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\n3. What TB-500 is studied to do: Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\n4. Therefore for you: If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\n\n## Why ARA-290 might help you\n\n1. You have Sciatica — breakdown is outpacing repair.\n2. What keeps failing: Nerve compression, small-fiber loss, neuropathic pain signaling without tissue repair.\n3. What ARA-290 is studied to do: Studied for nerve repair and small-fiber regeneration in neuropathy models.\n4. Therefore for you: If that layer is part of your problem, ARA-290 is discussed because it targets repair (nerve / innervation) — not because it masks pain.\n\n## How these fit together\n\nEach compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.\n- Retatrutide → metabolic load / body weight\n- BPC-157 → structure / tissue\n- TB-500 → inflammation clearance / repair-cell migration\n- ARA-290 → nerve / innervation\n\nPrimary focus of this slug: Retatrutide. Others are in scope because the same condition breaks down on multiple layers.\n\n## What the evidence actually shows\n\nRetatrutide human data come from phase 2 and phase 3 trials in people with obesity. In one phase 2 trial, the 12 mg dose produced mean weight loss of 24.2% at 48 weeks versus 2.1% on placebo (human tier). Larger phase 3 results (TRIUMPH-1) showed up to","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c4","text":"No published human trials test any of these compounds directly for sciatica or compressive radiculopathy.","tier":"human","weight":0.8,"section":"What we do not know","slot":null,"interaction_risk":false,"status":"active","source_ids":[],"source_status":"unsourced","why_material":"Clarifies the gap between available data and the condition.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c1","text":"Retatrutide produced mean 24.2% weight loss at 48 weeks (12 mg) in a phase 2 human obesity trial versus 2.1% placebo.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes human weight-loss magnitude relevant to mechanical load reduction.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c3","text":"ARA-290 improved neuropathic symptoms and corneal nerve density in small human trials of sarcoidosis and diabetes neuropathy.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s3"],"source_status":"sourced","why_material":"Highest-tier human data among the nerve-focused compounds.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c2","text":"BPC-157 improved rat sciatic nerve healing after transection in animal models.","tier":"preclinical","weight":0.5,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s2"],"source_status":"sourced","why_material":"Provides the main evidence layer for its tissue-repair discussion.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301972","title":"Triple–Hormone-Receptor Agonist Retatrutide for Obesity","quote":"At 48 weeks, the least-squares mean percentage change in the retatrutide groups was −24.2% in the 12-mg group, as compared with −2.1% in the placebo group.","summary":"Phase 2 trial results showing dose-dependent weight loss in humans with obesity.","claim_ids":["c1"],"link_status":"http_403","quote_status":"unverified","hash":"35d249b069391c30535d1995647bfae2e06e727039ca53313369414d20a4c2ea"},{"id":"s2","type":"pubmed","url":"https://link.springer.com/article/10.1186/s13018-019-1242-6","title":"Stable gastric pentadecapeptide BPC 157 can improve the healing of transected sciatic nerve","quote":"BPC 157 markedly improved rat sciatic nerve healing.","summary":"Rat study on sciatic nerve transection repair.","claim_ids":["c2"],"link_status":"ok","quote_status":"unverified","hash":"442897133f2fc6c705b64c63851b0fa691a799f4ab544068383af5635489c823"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5741312/","title":"Targeting the innate repair receptor to treat neuropathy","quote":"In patients with sarcoidosis, ARA290 significantly improved neuropathic and autonomic symptoms... initiated a regrowth of small nerve fibers in the cornea.","summary":"Human data on ARA290 in small-fiber neuropathy.","claim_ids":["c3"],"link_status":"ok","quote_status":"unverified","hash":"ccb4e4895092a7ca4bf37627afc301c9a027904096b0cfff7ef28d9a2cf02fd6"}],"anecdotal_sources":[],"scientific_sources":[{"id":"s1","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301972","title":"Triple–Hormone-Receptor Agonist Retatrutide for Obesity","quote":"At 48 weeks, the least-squares mean percentage change in the retatrutide groups was −24.2% in the 12-mg group, as compared with −2.1% in the placebo group.","summary":"Phase 2 trial results showing dose-dependent weight loss in humans with obesity.","claim_ids":["c1"],"link_status":"http_403","quote_status":"unverified","hash":"35d249b069391c30535d1995647bfae2e06e727039ca53313369414d20a4c2ea"},{"id":"s2","type":"pubmed","url":"https://link.springer.com/article/10.1186/s13018-019-1242-6","title":"Stable gastric pentadecapeptide BPC 157 can improve the healing of transected sciatic nerve","quote":"BPC 157 markedly improved rat sciatic nerve healing.","summary":"Rat study on sciatic nerve transection repair.","claim_ids":["c2"],"link_status":"ok","quote_status":"unverified","hash":"442897133f2fc6c705b64c63851b0fa691a799f4ab544068383af5635489c823"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5741312/","title":"Targeting the innate repair receptor to treat neuropathy","quote":"In patients with sarcoidosis, ARA290 significantly improved neuropathic and autonomic symptoms... initiated a regrowth of small nerve fibers in the cornea.","summary":"Human data on ARA290 in small-fiber neuropathy.","claim_ids":["c3"],"link_status":"ok","quote_status":"unverified","hash":"ccb4e4895092a7ca4bf37627afc301c9a027904096b0cfff7ef28d9a2cf02fd6"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"retatrutide-sciatica","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":4,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":4,"claims_total":4,"sources":3,"anecdotal":0,"scientific":3,"user_reports":0,"questions":0,"evidence_ingests":0}}